SOPHiA GENETICS announced that RareCyte Inc. is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM? Platform to complement its Precision Biology Services portfolio.

The company will use SOPHiA GENETICS to provide DNA sequencing of circulating tumor cells and cell-free DNA for testing of cancer patients. By integrating the SOPHiA DDM? Platform for bioinformatics support, RareCyte will enhance their workflow with dedicated filtering features and a rich knowledge base to identify variants of interest to provide researchers with highly accurate analytics and insights within hours.

With the SOPHiA DDM? Platform, RareCyte will retain ownership of its complete database and will have access to reproducible data to help accelerate clinical studies in the oncology space. The SOPHiA GENETICS technology will help RareCyte's team of scientists and engineers as they continue to develop next-generation products and services that advance precision medicine and biomedical research.